CVC faces shareholder revolt over €10.7bn Recordati take-private
CVC Capital Partners and GBL are attempting a 10.7 billion euro take-private acquisition of Recordati at 53 euro per share. Palliser Capital and Fairlight are opposing the valuation. The deal is complicated by internal CVC conflicts, as different funds within the firm are positioned on opposite sides of the transaction. Activists and board members are currently debating governance and whether the deal represents self-enrichment through an internal fund-to-fund sale.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The take-private offer for Recordati is valued at 10.7 billion euro.
- ✓ The current bid price is 53 euro per share.
- ✓ Palliser Capital opposes the current valuation of the offer.
What changed
Reports now indicate that different CVC funds are on opposing sides of the deal and that the transaction is viewed by some as an internal fund-to-fund sale.
Live updates
-
CVC faces internal conflict and activist pushback over 10.7 billion euro Recordati bid
CVC Capital Partners and GBL are attempting a 10.7 billion euro take-private acquisition of Recordati at 53 euro per share. Palliser Capital and Fairlight are opposing the valuation. The deal is complicated by internal CVC conflicts, as different funds within the firm are positioned on opposite sides of the transaction. Activists and board members are currently debating governance and whether the deal represents self-enrichment through an internal fund-to-fund sale.
Why it matters
Recordati is an Italian pharmaceutical group. This acquisition involves Respighi BidCo, a vehicle controlled by CVC and GBL. The dispute centers on whether the revised offer price sufficiently compensates shareholders.
What is confirmed
- The take-private offer for Recordati is valued at 10.7 billion euro.
- The current bid price is 53 euro per share.
- Palliser Capital opposes the current valuation of the offer.
Still unconfirmed
- The transaction is being criticized as an instance of self-enrichment due to its nature as a fund-to-fund sale.
- There is disagreement within the board regarding governance and valuation.
What to watch next
- The expiration date of the tender offer
- The response from independent administrators regarding the 53 euro bid
confidence 80%Sources used for this update (2)
- www.milanofinanza.it — Recordati, il rebus dell’opa fra diversi fondi di Cvc: che ...
- www.headliner.nl — CVC Capital Partners onder vuur wegens zelfverrijking bij ...
-
Palliser and Fairlight challenge CVC and GBL bid for Recordati
Palliser Capital and Fairlight are contesting the revised 53 euro per share take-private offer for Recordati from Respighi BidCo, a vehicle controlled by CVC and GBL. While Recordati stock trades near the offer price, Palliser Capital has confirmed it does not support the current valuation. The dissenting investors are now requesting that the board of directors clarify the positions of independent administrators following the 3.3% increase in the bid price.
Why it matters
CVC and GBL initially launched their bid on August 31. The current 53 euro per share offer follows a previous attempt that minority investors claimed undervalued the company.
What is confirmed
- Palliser Capital does not support the 53 euro per share offer from CVC and GBL.
- Recordati is trading near the 53 euro per share price offered by Respighi BidCo.
Still unconfirmed
- Fairlight is contesting the 53 euro take-private offer.
- Investors are asking the board to clarify the position of independent administrators after the 3.3% bid increase.
What to watch next
- The expiration of the acceptance period on October 23.
- The response from Recordati's independent directors regarding the bid's adequacy.
confidence 90%Sources used for this update (4)
- markets.ft.com — Groep Brussel Lambert NV, GBLB:BRU summary - FT.com
- www.marketscreener.com — Recordati, Palliser Capital challenges EUR53 takeover bid ...
- www.pehub.com — Permira mulls $3.5bn Octus sale to London Stock Exchange ...
- www.ilgiornaleditalia.it — Recordati, Palliser e Fairlight contestano l'Opa a €53 di Cvc ...
-
CVC, GBL raise Recordati take-private bid to €53 per share
CVC Capital and Groupe Bruxelles Lambert raised their take-private bid for Recordati to €10.5 billion and €53 per share, extending the acceptance period to October 23. The increased offer comes after minority investors like Palliser Capital argued the initial offer undervalued the company. Recordati's stock price rose following the public challenge. The bid was initially launched on August 31.
Why it matters
The take-private bid is significant due to its large size and the public dissent from minority investors. Recordati is an Italian drugmaker, and the deal would take the company private. The initial bid faced a shareholder revolt, leading to the increased offer.
What is confirmed
- CVC and GBL raised their cash offer for Recordati to €10.5 billion and €53 per share.
- The acceptance period for the offer was extended to October 23.
- The initial bid for Recordati was launched on August 31.
What to watch next
- Recordati shareholder response to the increased offer
- CVC and GBL's future actions if the offer is not accepted
- The delisting process for Recordati if the offer is successful
confidence 90%Sources used for this update (4)
- en.ilsole24ore.com — CVC and GBL raise their bid for Recordati to 53 euros per ...
- pipelineroad.com — CVC raises Recordati take-private offer to €10.5bn and €53 ...
- recordati.com — Investors - Public Tender Offers - Recordati
- www.globalbankingandfinance.com — CVC, GBL Raise Takeover Bid for Recordati to €53 Per Share
-
CVC faces shareholder revolt over €10.7bn Recordati take-private
CVC Capital's €10.7 billion take-private bid for Recordati is facing a shareholder revolt, with minority investors like Palliser Capital arguing the offer price of 51.29 euros per share undervalues the company. Recordati's stock price has risen following the public challenge from Palliser Capital. The bid was launched on August 31. CVC has dropped its pursuit of Bodycote, clearing the path for Veritas' $2.5 billion takeover.
Why it matters
The shareholder revolt against CVC Capital's take-private bid for Recordati highlights tensions between the private equity firm and minority investors. Recordati's stock price has responded to the public challenge, indicating market skepticism about the bid. CVC's decision to abandon its pursuit of Bodycote may be seen as a strategic shift.
What is confirmed
- CVC Capital launched a €10.7 billion take-private bid for Recordati on August 31.
- The offer price is 51.29 euros per share.
- Recordati's stock price has risen following a public challenge from Palliser Capital.
- CVC Advisers abandoned its pursuit of Bodycote on September 28.
- Veritas Capital won Bodycote's backing for its £1.85 billion ($2.45 billion) takeover offer.
What to watch next
- Recordati shareholder response to CVC's bid
- CVC's next move in the Recordati take-private bid
- Veritas' completion of Bodycote takeover
confidence 90%Sources used for this update (2)
- www.proactiveinvestors.co.uk — CVC walks away from Bodycote, clearing path for Veritas
- live.euronext.com — CVC drops Bodycote pursuit, clears path for Veritas' $2.5 ...
-
CVC faces shareholder revolt over €10.7bn Recordati take-private
CVC Capital is facing a shareholder revolt over its €10.7 billion take-private bid for Recordati. Minority investors, including Palliser Capital, are pushing back against the deal, arguing that the offer price of 51.29 euros per share undervalues the company. Recordati's stock price has risen following the public challenge from Palliser Capital. The bid was launched on August 31.
Why it matters
The take-private deal has sparked controversy among Recordati's shareholders, with some investors questioning the fairness of the offer price. CVC Capital, in partnership with Belgian investment group GBL, launched the bid to take Recordati private. The deal's success is uncertain as minority investors continue to voice their opposition.
What is confirmed
- Recordati's market value is 10.8 billion euros.
- CVC Capital has €212 billion of assets under management.
- The take-private bid for Recordati was launched on August 31.
Still unconfirmed
- Italian pharmaceutical companies Angelini Pharma and Recordati are negotiating a merger.
What to watch next
- Recordati's board response to Palliser Capital's challenge
- CVC Capital's next move to address shareholder concerns
- the outcome of the tender offer
confidence 80%Sources used for this update (8)
- markets.ft.com — Recordati Industria Chimica e Farmaceutica S.p.A.
- www.stockopedia.com — RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA | Brief: CVC ...
- www.akm.ru — Italian pharmaceutical companies Angelini Pharma and ...
- www.cvc.com — Share Information - CVC
- www.marketscreener.com — CVC Capital Partners plc: Official Announcements - Stock ...
- pharmainfocus.com.au — $17.7B bid to take pharma private
- markets.ft.com — Recordati Industria Chimica e Farmaceutica S.p.A.
- ig.cvc.com — Investor Presentations – CVC Income & Growth
-
CVC Faces Shareholder Revolt Over Recordati Take-Private
CVC Capital faces a shareholder revolt as minority investors push back against a take-private and delisting proposal for Recordati. Palliser Capital has issued a letter to Recordati's board of directors urging them to withdraw support for the tender offer, arguing that the proposed pricing is materially undervalued. The British fund contends that the offer price of 51.29 euros per share, launched on August 31, fails to represent a fair valuation for the company. Recordati stock has edged higher following the public challenge from Palliser Capital against the CVC-GBL takeover bid.
Why it matters
Take-private transactions involving large private equity firms often trigger friction with minority shareholders regarding valuation fairness. When buyout groups attempt to delist a publicly traded company, institutional investors frequently scrutinize the financial terms to ensure adequate compensation. The intervention by Palliser Capital highlights the growing willingness of activist funds to publicly challenge board-backed buyout offers.
What is confirmed
- CVC faces a shareholder revolt over a 10.7 billion euro Recordati take-private and delisting plan.
- Palliser Capital issued a letter to Recordati's board urging the withdrawal of support on a tender offer it views as materially undervalued.
- The takeover bid was launched on August 31 at a price of 51.29 euros per share.
- Recordati stock edged higher as Palliser challenged the CVC takeover offer.
What to watch next
- Recordati board response to Palliser Capital's letter
- Potential adjustments to the CVC-GBL tender offer price
- Further actions by minority shareholders regarding the delisting
confidence 100%Sources used for this update (8)
- ft.com — CVC faces shareholder revolt over €10.7bn Recordati take-private
- Business Wire — Palliser Capital Issues Letter to Recordati’s Board of Directors Urging Withdrawal of Support on Materially Undervalued Tender Offer
- marketscreener.com — CVC, shareholders push back against €10.7bn Recordati delisting
- marketscreener.com — Certain Recordati Minority Shareholders Raise Concerns Over CVC Capital's Takeover Offer
- Finimize — Activist Investor Tells Recordati To Push Back On Takeover Price
- marketscreener.com — Palliser Capital urges Recordati's board to withdraw support for CVC-GBL offer
- Ad-hoc-news.de — Recordati stock edges higher as Palliser challenges CVC takeover offer
- en.ilsole24ore.com — Recordati: Palliser Capital writes to the board urging it to reject the CVC-GBL takeover bid
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community